



A Journal of the Gesellschaft Deutscher Chemiker

Angewandte Chemie

GDCh

International Edition

www.angewandte.org

Accepted Article

Title: An Activity-based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells

Authors: Anuj K. Yadav, Christopher J. Reinhardt, Andres S. Arango, Hannah C. Huff, Liang Dong, Michael G. Malkowski, Aditi Das, Emad Tajkhorshid, and Jefferson Chan

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Angew. Chem. Int. Ed.* 10.1002/anie.201914845
Angew. Chem. 10.1002/ange.201914845

Link to VoR: <http://dx.doi.org/10.1002/anie.201914845>
<http://dx.doi.org/10.1002/ange.201914845>

RESEARCH ARTICLE

An Activity-based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells

Anuj K. Yadav,^{+[a]} Christopher J. Reinhardt,^{+[a]} Andres S. Arango,^[b] Hannah C. Huff,^[a] Liang Dong,^[c] Michael G. Malkowski,^[c] Aditi Das,^[d] Emad Tajkhorshid,^[b] and Jefferson Chan^{[a]*}

Abstract: Cyclooxygenase-2 (COX-2) overexpression is prominent in inflammatory diseases, neurodegenerative disorders, and cancer. Directly monitoring COX-2 activity within its native environment poses an exciting approach to account for and illuminate the effect of the local environments on protein activity. Herein, we report the development of CoxFluor, the first activity-based sensing approach for monitoring COX-2 within live cells with confocal microscopy and flow cytometry. CoxFluor strategically links a natural substrate with a dye precursor to engage both the cyclooxygenase and peroxidase activities of COX-2. This catalyzes the release of resorufin and the natural product, as supported by molecular dynamics and ensemble docking. CoxFluor enabled the detection of oxygen-dependent changes in COX-2 activity that are independent of protein expression within live macrophage cells.

Introduction

Cyclooxygenase (COX, E.C. 1.14.99.1) is the key biosynthetic enzyme that initiates the synthesis of prostaglandins from their linear lipid precursor, arachidonic acid (AA).^[1–3] After production, the prostaglandins function as important lipid-based mediators that regulate physiological processes, such as gastric epithelial protection, hemostasis, and sodium metabolism.^[4,5] At higher concentrations the prostaglandins act as potent pro-inflammatory compounds through the production of cytokines.^[6,7] These prostaglandins can be further elaborated by a variety of tissue-specific isomerases and synthases to afford the entire gamut of prostanoids (AA-derived prostaglandins).^[5]

Two isoforms of human COX have been identified (COX-1 and -2), which display a high level of structural homology (~60% sequence identity).^[8] Both isoforms catalyze the rate-limiting step for production of prostaglandin H₂ (PGH₂) through distinct cyclooxygenase and peroxidase active sites. The major

difference between the two isoforms is their expression profile: COX-1 is constitutively expressed in most cell types, whereas COX-2 expression can either be constitutive or induced for rapid prostaglandin production depending on the tissue type.^[2,4,9–12] COX overexpression represents a prominent phenotype in inflammation,^[13,14] neurodegenerative disorders,^[15] and cancer.^[10,16,17] For example, high expression levels and cross-talk with inducible nitric oxide synthase in cancer can correlate with poor clinical outcomes through increased angiogenesis, proliferation, and cell migration.^[18–22] It is important to note that a variety of factors beyond concentration can influence COX-2 activity (e.g., substrate concentration, allosteric regulators, and post-translational modifications), especially *in vivo*.^[23–27]

To date, only a limited number of strategies have been introduced for detecting COX-2 in living systems. For example, selective inhibitors of COX-2 have been radiolabeled^[28–34] or appended to dyes^[35,36] for PET/SPECT or fluorescence imaging, respectively. These imaging agents report on relative COX-2 expression profiles; however, they remain in a constant 'on' state, regardless of whether they are bound to COX-2. More recently, activatable fluorescent inhibitors have been reported that afford an "off-on" response, where protein binding sequesters the inhibitor away from the fluorophore, disrupts the inhibitor-mediated fluorescence quenching, and renders the protein-small-molecule adduct fluorescent.^[37,38] Despite these notable improvements, these technologies only report on whether COX-2 is present, but not whether the enzyme is catalytically active.

Activity-based sensing (ABS) represents a powerful detection strategy that relies on selective chemical reactivity. In contrast to binding-based methods, ABS provides a direct readout for the analyte or protein's activity, rather than its concentration, enabling a more complete depiction of its contribution within living systems.^[39,40] A variety of fluorescent probes have been reported for the detection of enzyme activity. However most display broad reactivity across a class of enzymes.^[41] The development of isoform-selective activity-based sensors remains challenging due to the generally high structural similarities among isoforms. To date, some examples exist; however, they have largely targeted promiscuous enzymes involved in xenobiotic metabolism (e.g., cytochrome P450, monoamine oxidase, aldehyde dehydrogenase).^[42–46] To address these limitations, we developed CoxFluor, the first isoform-selective, activity-based fluorescent probe for COX-2. Isoform selectivity was achieved by leveraging the subtle differences in the size and dynamics of the cyclooxygenase active sites.^[2,47] CoxFluor enabled the validation of COX-2 inhibitors within *in vitro* assays, was successfully applied for live-cell imaging and flow cytometry, and illustrated oxygen-dependent COX-2 activity within live macrophage.

Results and Discussion


CoxFluor consists of 3,7-dihydroxyphenoxazine (reduced form of resorufin) linked to AA through a cleavable amide bond. We proposed this design with the hypothesis that the lipid tail could serve as a substrate for COX-2 in a manner similar to the AA (Scheme 1a). After binding within the cyclooxygenase active site, the probe could undergo hydrogen atom abstraction by the

- [a] Dr. A. K. Yadav, C. J. Reinhardt, H. C. Huff, Prof. E. Tajkhorshid, Prof. J. Chan
Department of Chemistry, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801 United States
E-mail: jeffchan@illinois.edu
- [b] A. S. Arango, Prof. A. Das, Prof. E. Tajkhorshid
Center for Biophysics and Quantitative Biology, Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801 United States
- [c] Dr. L. Dong, Prof. M. G. Malkowski
Department of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14203, United States
- [d] Prof. A. Das
Department of Comparative Biosciences
University of Illinois at Urbana-Champaign
Urbana, Illinois, 61801 United States

[+] These authors contributed equally to this work.
Supporting information for this article is given via a link at the end of the document.


RESEARCH ARTICLE

Scheme 1. (a) Biosynthesis of PGG₂ from AA by COX. (b) Proposed mechanism of COX-catalyzed resorufin production via CoxFluor-PGG₂ intermediate oxidation by Compound I (π cationic porphyrin radical) or Compound II (oxyferryl). The reaction between two CoxFluor-PGG₂ intermediate radicals, dismutation, and hydrolysis are omitted for simplicity.



enzyme's Tyr385, followed by dioxygenation and cyclization to afford the CoxFluor-PGG₂ intermediate. Subsequent translocation to the peroxidase active site and oxidation by Compound I or II could yield an unstable oxygen-centered resorufin radical followed by dismutation and amide hydrolysis to release the fluorescent product and either PGG₂ or PGG₂ (after reduction, Scheme 1b).^[1,48–50] When proposing this structure, we hypothesized that we could utilize the bulky dye to prevent COX-1 binding and catalysis. This was based on previous reports that indicate COX-1 is unable to accommodate large groups at the carboxylate^[2] and that this moiety provides critical interactions with Arg120 for binding.^[51–53] On the other hand, COX-2's larger substrate pocket and expanded substrate scope, including amides, suggested that CoxFluor should be competent for catalysis.^[54]

Scheme 2. Synthesis of CoxFluor from resazurin.



The synthesis of CoxFluor began with the Zn-mediated reduction of resazurin, followed by acetylation with acetic anhydride to afford **1** in 63% yield over two steps.^[55] This intermediate was then coupled to arachidonyl chloride in the presence of potassium iodide to afford **2** in 49% yield. Finally, treatment of **2** with sodium methoxide (generated *in situ*) facilitated acetyl deprotection and provided CoxFluor in 68% yield (overall 21% over 4 steps, Scheme 2).

With CoxFluor in hand, we first evaluated its response to recombinant human COX-2. Treatment of CoxFluor ($\Phi_F = 0.29$, $\epsilon = 820 \text{ M}^{-1}\text{cm}^{-1}$ at 572 nm) with COX-2 resulted in the production of resorufin ($\Phi_F = 0.55$, $\epsilon = 73,000 \text{ M}^{-1}\text{cm}^{-1}$ at 573 nm)^[56] and PGG₂ (confirmed by LC-HRMS, Figure S1) with a 41-fold fluorescent turn-on response (Figure 1a).

To confirm that activation was a consequence of enzyme-catalyzed oxidation rather than unbiased peroxidase activity, we prepared a control compound, Ctrl-CoxFluor, where the AA lipid was replaced with the saturated lipid tail (arachidic acid, Scheme S1). Ctrl-CoxFluor proved to be unreactive under the same reaction conditions (Figure 1b), strongly suggesting that the signal enhancement observed for CoxFluor was due to enzymatic activity. Under steady state conditions, CoxFluor underwent oxidation to resorufin with a k_{cat} of 19 min^{-1} and K_m of $22 \mu\text{M}$ (Figure 1c). The K_m values are similar to those obtained for arachidonyl ethanolamide ($K_m = 24 \mu\text{M}$) and were within an order of magnitude of AA ($K_m = 6 \mu\text{M}$) and the measured rate for turn-over is within 100-fold of the natural substrate cyclooxygenase activity.^[54] Moreover, CoxFluor's fluorescence response was inhibited by both indomethacin and celecoxib (Figure 1d). This suggests that CoxFluor can be utilized to identify and/or evaluate COX-2 inhibitors, overcoming key drawbacks in existing methodologies that require radiolabeled compounds, purification of intermediates or products, or coupled-enzyme systems.^[57,58] This also provides further support for the formation of a CoxFluor-PGG₂ intermediate because both inhibitors bind within the cyclooxygenase active site of the protein.^[59,60]

Isoform selectivity was evaluated by incubating CoxFluor with COX-1 isolated from bovine vesicles, where a minimal change in fluorescence was observed over the course of 4 h (1.3-fold fluorescence enhancement, 5% of COX-2 response, Figure S2). Off-target activation was also assessed against a panel of enzymes that possess closely related activities (lipoxygenase, peroxidase, catalase), could potentially cleave the amide (esterase), or are capable of metabolizing AA analogs (cytochrome P450s).^[61] Even in the presence of 10-fold excess enzyme, CoxFluor displayed good selectivity against all of the tested enzymes (Figure 1e). Likewise, no undesirable activation was observed when CoxFluor was incubated with various biologically relevant reactive oxygen species, reactive nitrogen species, or other cellular oxidants/reductants (Figure 1f and S3). Moreover, no bleaching was observed when resorufin was treated

RESEARCH ARTICLE

with the same panel of reactive oxygen and nitrogen species (Figure S3). Importantly, incubation of CoxFluor with COX-2 in the presence of glutathione (GSH, 1 mM) maintained significant COX-2-specific fluorescence enhancement, indicating the potential for use for live-cell imaging (Figure S4). This is in contrast to Amplex® Red-based assays, which display cross-reactivity with GSH in the presence of peroxidases^[62] or direct quenching of the radical intermediate.^[50]




Figure 1. (a) Relative fluorescence for CoxFluor (10 μM) incubated with COX-2 (250 nM) and hemin (1 μM) over the course of 4 h. (b) Relative fluorescent intensity of CoxFluor and Ctrl-CoxFluor after incubation with COX-2 (250 nM) and hemin (1 μM) for 4 h. (c) Michaelis-Menten kinetics for COX-2-catalyzed (50 nM) release of resorufin in the presence of hemin (200 nM). (d) Inhibition of COX-2 (250 nM) and hemin (1 μM) by indomethacin (10 μM) and celecoxib (10 μM). (e) Relative fluorescence for CoxFluor incubated COX-2 (0.101 U), a panel of enzymes (10-fold excess) or (f) panel of reactive oxygen/nitrogen species (500 μM , 50 equiv.). All experiments were conducted at room temperature in 100 mM Tris HCl buffer (pH 8.0) except MPO, and 5-LOX (additional information in the Supporting Information). All data is reported as the mean \pm standard deviation ($n = 3$) for parts b, d, e and f or the error from fitting for part c. Parts a/c and b/d-f were performed according to the fluorimeter and plate reader assays, respectively.

To further investigate the mechanism of CoxFluor activation by COX-2, we employed molecular dynamics (MD) and ensemble docking. Previous structures of COX-1 (PDB 5U6X)^[63] and COX-

2 (PDB 5KIR)^[64] were selected, ligands were removed and the holoenzyme was simulated in explicit water over a period of 200 ns. Importantly, no global differences were observed for the peptide backbone across a panel of COX-1 and COX-2 structures, even in the presence of ligands and substrate (www.rcsb.org, all root-mean-standard-deviation < 2.5 Å, Table S1-2 and Figure S5).^[65] Next, CoxFluor was docked into each pose along the simulation trajectory to probe the most probable binding modes (based on the predicted binding score),^[66] where clear differences in the number and area available for binding were observed both overall and within the cyclooxygenase active site of COX-2 as compared to COX-1 (Figure 2a-c and S6). This finding is consistent with the difference in solvent accessible surfaces harbored within each cyclooxygenase active site.^[2] CoxFluor also docks in a similar location to the reported indomethacin fluorescent inhibitors (Figure S7),^[36,67] further supporting the proposed cyclooxygenase-dependent release of resorufin (Scheme 1b).




Figure 2. Molecular dynamics and ensemble docking studies of (a) COX-1 and (b) COX-2 with CoxFluor (green). Initial protein structures were prepared from PDB 5U6X and 5KIR and crystal bound AA (orange) is superimposed for comparison from PDB 1DIY and 3HS5, respectively. Structures display an overlay of all CoxFluor docked poses with scoring less than or equal to -7 kcal/mol. The heme from the simulation is represented as a ball and stick model to distinguish the cyclooxygenase and peroxidase active sites. (c) Percent of CoxFluor poses within the docking score binding affinities. (d) Competent binding of CoxFluor within the cyclooxygenase active site. Tyr385 (yellow) is oriented for hydrogen atom extraction from either CoxFluor (green) or AA (orange, PDB 3HS5).

To begin to interrogate the sequence of events, CoxFluor and the CoxFluor-PGG₂ intermediate were docked within COX-2. Consistent with the proposed mechanism, CoxFluor binds significantly at the cyclooxygenase active site (66/597 poses at -7 kcal/mol cutoff). On the other hand, the CoxFluor-PGG₂ intermediate displayed increased binding at the peroxidase active site for oxidation by either Compound I or Compound II (356/368 poses at -7 kcal/mol cutoff). This increased selectivity for the CoxFluor-PGG₂ intermediate at the peroxidase active site is consistent over all spontaneous interactions (Figure S8). These results are consistent with peroxidase oxidation^[68] of CoxFluor-PGG₂ in a similar manner to Amplex® Red^[50] and 2,2'-azinobis(3-ethylbenzothiazolinesulfonic acid) oxidation by horseradish peroxidase.^[49,69] Finally, to confirm that CoxFluor can adopt the

RESEARCH ARTICLE

requisite conformation for oxidation by the active site Tyr385, CoxFluor was docked within the cyclooxygenase active site and compared to crystal bound AA (PDB 3HS5).^[70] Structural comparisons indicate that CoxFluor can bind within the cyclooxygenase active site with proper orientation for oxidation (Figure 2d). Similar poses are also observed within the larger box that contains both the cyclooxygenase and peroxidase active sites. Together, these results suggest that CoxFluor binds within the substrate binding pocket or adjacent solvent-exposed sites to undergo oxidation and formation of the CoxFluor-PGG₂ intermediate. After dissociation from the active site, the intermediate displays increased binding to the peroxidase active site for oxidation by Compound I or Compound II and subsequent release of resorufin.

Prior to performing cellular experiments, we evaluated CoxFluor's stability and biocompatibility. Negligible fluorescence response was observed after 8 h of incubation at room temperature or 37 °C (Figure S9) and typical staining conditions yielded minimal toxicity in HEK 293T and RAW 264.7 macrophage cells (Figure S10). Next, we generated a transiently transfected HEK 293T cell line over-expressing human COX-2. GSH depletion was performed with *N*-ethylmaleimide (NEM)^[71] prior to staining because GSH can generate^[62] or quench radical intermediates of peroxidase-based probes, thereby complicating the interpretation of results.^[50,72] Moreover, past work has demonstrated that COX-2 inhibitors (e.g., celecoxib analogs and indomethacin) can alter GSH levels,^[73–76] which is consistent with our initial experimental observations (Figure S11). After incubation with CoxFluor for 3 h we observed a 1.2-fold fluorescence increase for transfected cells compared to the control, and no fluorescence enhancement was observed upon treatment with indomethacin (Figure S12).

Next, we applied CoxFluor for the detection and imaging of endogenous COX-2 activity within RAW 264.7 murine macrophage. As a key player in inflammatory and immune responses, macrophages undergo phenotypic changes to pro-inflammatory or anti-inflammatory states upon stimulation.^[77] Because COX-2 activity is the rate-limiting step in prostaglandin biosynthesis (pro-inflammatory mediators), COX-2 expression and subsequent prostaglandin production can be measured in well-established lipopolysaccharide (LPS)-induced inflammation models as a biomarker for inflammation.^[3,78–83] To date, these studies typically rely on mRNA quantification, western blot analysis, or downstream product quantification (e.g., ELISA assays) rather than direct quantification of COX-2 activity. This is due to the lack of isoform selectivity in current COX assays. First, we measured the effect of LPS stimulation time on COX-2's specific activity in RAW 264.7 macrophage lysates. Variations due to GSH fluctuations were again minimized using NEM, which we and others have shown does not affect COX activity (Figure S13).^[84] Within the first 4 h of activation only a modest 2.4-fold increase in COX-2 activity was observed. Over the next several hours, the activity increased in a linear fashion to a maximum of 17.6-fold at 19 h (Figure S14). These results are similar to previous reports of prostaglandin biosynthesis within both murine^[82] and human^[81] macrophage cells under LPS-stimulated conditions. The activity differences were then confirmed within live cells using both confocal microscopy (Figure 3) and flow cytometry (Figure S15). Rather than using NEM, we pre-treated with buthionine sulfoximine (BSO), a γ -glutamylcysteine synthase inhibitor, because it is a less cytotoxic alternative.^[85,86] Under these conditions we observed a 1.2-fold fluorescent enhancement for LPS-stimulated cells relative to the control using confocal microscopy and a 1.6-fold increase in median fluorescence for cells activated for 19 h as compared to 4 h with flow cytometry (Figure 3 and S15). By monitoring the ratio of fluorescence from CoxFluor stained cells to CoxFluor stained cells treated with

indomethacin it was possible to clearly identify COX-2 activity across activation states (M0 versus M1, Figure S15). Finally, the ability of CoxFluor to detect activity changes without GSH depletion was confirmed with flow cytometry, under similar conditions, where a 1.2-fold increase in activity was observed after 19 h LPS-activation relative to 4 h LPS-stimulated cells (Figure S16).




Figure 3. Confocal imaging of COX-2 activity in (a) control, (b) LPS-stimulated (1 μ M), and (c) indomethacin-treated (10 μ M), LPS stimulated RAW 264.7 cells after 4 h incubation with CoxFluor (10 μ M) at 37 °C following treatment with BSO (began 19 h prior to staining, 200 μ M). Scale bar (white) represents 10 μ m. (d) Quantified data. Values are reported as the mean \pm standard deviation ($n = 3$). Statistical analysis was performed using one-way ANOVA ($\alpha = 0.05$). **, $p < 0.01$.

Finally, we were interested in determining whether COX-2 activity can be regulated beyond the protein level. We hypothesized that oxygen concentrations may influence COX-2 activity because oxygen serves as a substrate, but can also bind ferric heme prosthetic groups to yield an off-cycle resting state.^[87] The effect of oxygen on COX-2 activity was evaluated in live RAW 264.7 macrophage cells after a 19 h activation with LPS. The cells were then stained under normoxic (~21%) or hypoxic conditions (prepared using AneroPack® for < 0.1% oxygen in a sealed container) and the fluorescent response was monitored with flow cytometry. Interestingly, higher activity was observed under hypoxic conditions, as indicated by a substantial shift in the median fluorescence (Figure 4a-c). Moreover, this increase in fluorescence was COX-2-dependent, where treatment with indomethacin resulted in a 12% decrease in the ratio of median fluorescence for hypoxic to normoxic M1 macrophages (Figure 4d). To confirm the result and evaluate the dose-dependency of oxygen, we repeated the experiment under a 1 or 0.1% oxygen atmosphere. Here we observe an oxygen-dependent decrease in COX-2 activity (Figure 4d-e) that is independent of protein expression levels (Figure 4f). This provides strong evidence that the local cellular environment plays a critical role in the regulation of COX-2 activity. This finding also emphasizes the importance of measuring activity, in addition to transcriptional and translational levels. To the best of our knowledge, this represents the first example when an ABS approach has revealed activity differences that result from regulation beyond protein expression levels.

RESEARCH ARTICLE




Figure 4. Contour plots of flow cytometry data from live LPS-activated RAW 264.7 macrophage cells stained with CoxFluor (10 μ M) under (a) normoxic and (b) hypoxic conditions. (c) Quantified median fluorescence for hypoxic and normoxic cells. (d) Effect of indomethacin (20 μ M) treatment on the ratio of hypoxic to normoxic median fluorescence. (e) Median fluorescence of RAW 264.7 macrophage cells stained under 0.1% (red), 1.0% (grey), or 21% (blue) oxygen concentrations. (f) ELISA quantification of COX-2 protein expression levels in 25 μ g/mL protein lysates. Values are reported as the mean \pm propagated standard deviation ($n = 6$ for flow cytometry data; $n = 3$ indomethacin inhibition and ELISA data). All staining was performed following treatment with BSO (began 2 h prior to staining, 200 μ M) and oxygen dependent flow cytometry data was replicated on two separate days. Statistical analysis was performed with two-tail Student's t test for c, one-tail Student's t test for d, or one-way ANOVA for e ($\alpha = 0.05$). *, $p < 0.05$, ****, $p < 0.0001$.

Conclusion

It is critical to develop methods for studying the influence of the local environment on COX-2's enzymatic activity. While it is reasonable to postulate that substrate availability should affect reaction rates, the outcome is particularly difficult to predict within living systems. We turned to an ABS approach to overcome this key challenge. CoxFluor represents the first isoform-selective probe for measuring COX-2 activity. Strategic utilization of the bulky resorufin precursor and AA tail provided CoxFluor with the requisite selectivity for interrogating COX-2 biology in complex mixtures (e.g., in the presence of COX-1), where current inhibitors display imperfect selectivity.^[88] This isoform selectivity enables researchers to directly study COX-2 within its native environment, while accounting for factors beyond transcription and translation.^[89] Along these lines, we demonstrate that COX-2

activity can be regulated by oxygen availability within live cells. Taken together, these results suggest that CoxFluor will be a powerful tool for evaluating new therapeutics and for studying COX-2 in live cells.

Acknowledgements

The authors acknowledge the National Institutes of Health for support (R35GM133581 to J.C.; R01GM115386 to M.G.M.; P41GM104601 and R01GM123455 to E.T.; R01GM1155884 and R03DA04236502 to A.D.). This work was supported in part by the Alfred P. Sloan Fellowship (FG-2017-8964 to J.C.) and by the American Heart Association Scientist Development Grant (15SDG25760064 to A.D.). C.J.R. acknowledges the Chemistry-Biology Interface Training Grant (T32GM070421) and the Seemon Pines Graduate Fellowship for support. Simulations were performed using the National Science Foundation's computing resources through an XSEDE grant (TMGCA06N060 to E.T.) and PRAC allocation grant (ACI1713784 to E.T.). Major funding for the 500 MHz Bruker CryoProbe™ was provided by the Roy J. Carver Charitable Trust (Muscatine, Iowa; Grant #15-4521) to the School of Chemical Sciences NMR Lab. The Q-TOF Ultima mass spectrometer was purchased in part with a grant from the National Science Foundation, Division of Biological Infrastructure (DBI-0100085). We acknowledge Prof. Elvira de Mejia (Food Science and Human Nutrition, UIUC) for providing RAW 264.7 macrophage cells. We acknowledge the Core Facilities at the Carl R. Woese Institute for Genomic Biology for access to the Zeiss LSM 700 Confocal Microscope. Additionally, we acknowledge the Roy J. Carver Biotechnology Center at UIUC and Dr. Barbara Pilas for access to the BD LSR Fortessa Flow Cytometry Analyzer and for constructive discussions about instrumentation. We also thank Prof. Robert Gennis (Department of Biochemistry, UIUC) for access to the Strathkelvin oxygen electrode, Prof. H. Rex Gaskins (Department of Animal Sciences and Pathobiology, UIUC) and Emily (Jee-Wei) Chen (Department of Chemical and Biomolecular Engineering, UIUC) for access and assistance with the BioSpherix C-Chamber hypoxic incubator equipped with the corresponding OxyCycler C42 sub-chamber controller, and Daryl Meling and Amogh Kambalyal for the procurement and dissection of the bovine vesicles.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: activity-based sensing • bioimaging • fluorescent probes • isoform selectivity • molecular dynamics and ensemble docking

- [1] C. A. Rouzer, L. J. Marnett, *J. Lipid Res.* **2009**, *50*, S29–S34.
- [2] A. L. Blobaum, L. J. Marnett, *J. Med. Chem.* **2007**, *50*, 1425–1441.
- [3] D. L. DeWitt, *Biochim. Biophys. Acta* **1991**, *1083*, 121–134.
- [4] S. Kargman, S. Charleson, M. Cartwright, J. Frank, D. Riendeau, J. Mancini, J. Evans, G. O'Neill, *Gastroenterology* **1996**, *111*, 445–454.
- [5] E. M. Smyth, T. Grosser, M. Wang, Y. Yu, G. A. FitzGerald, *J. Lipid Res.* **2009**, *50*, S423–S428.
- [6] B. St-Jacques, W. Ma, *J. Neurochem.* **2011**, *118*, 841–854.
- [7] M. A. Liebert, J. O. Y. A. Williams, C. H. Pontzer, E. Shacter, *J. Interf. Cytokine Res.* **2000**, *298*, 291–298.
- [8] S. B. Appleby, A. Ristimäki, K. Neilson, K. Narko, T. Hla, *Biochem. J.* **1994**, *302*, 723–727.
- [9] R. N. Dubois, S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. A. Van De Putte, P. E. Lipsky, *FASEB J.* **1998**, *12*,

RESEARCH ARTICLE

- 1063–1073.
- [10] C. S. Williams, M. Mann, R. N. DuBois, *Oncogene* **1999**, *18*, 7908–7916.
- [11] L. Fagerberg, B. M. Hallström, P. Oksvold, C. Kampf, D. Djureinovic, J. Odeberg, M. Habuka, S. Tammasepp, A. Danielsson, K. Eklund, et al., *Mol. Cell. Proteomics* **2014**, *13*, 397–406.
- [12] N. S. Kirkby, M. V. Chan, A. K. Zaiss, E. Garcia-Vaz, J. Jiao, L. M. Berglund, E. F. Verdu, B. Ahmetaj-Shala, J. L. Wallace, H. R. Herschman, et al., *Proc. Natl. Acad. Sci.* **2015**, *113*, 434–439.
- [13] S. Kapoor, A. Burke, I. A. Mardini, B. F. McAdam, G. A. FitzGerald, A. Habib, J. A. Lawson, *J. Clin. Invest.* **2000**, *105*, 1473–1482.
- [14] T. A. Samad, K. A. Moore, A. Sapirstein, S. Billet, A. Allchorne, S. Poole, J. V. Bonventre, C. J. Woolf, *Nature* **2001**, *410*, 471–475.
- [15] P. Teismann, K. Tieu, D.-K. Choi, D.-C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, S. Przedborski, *Proc. Natl. Acad. Sci.* **2003**, *100*, 5473–5478.
- [16] B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, C. V. Rao, *Cancer Res.* **2000**, *60*, 293–297.
- [17] H. Chen, W. Cai, E. S. H. Chu, J. Tang, C. C. Wong, S. H. Wong, W. Sun, Q. Liang, J. Fang, Z. Sun, et al., *Oncogene* **2017**, *36*, 4415–4426.
- [18] S. L. Kargman, G. P. O'Neill, P. J. Vickers, J. F. Evans, J. A. Mancini, S. Jothy, *Cancer Res.* **1995**, *55*, 2556–2559.
- [19] D. Basudhar, S. A. Glynn, M. Greer, V. Somasundaram, J. H. No, D. A. Scheiblin, P. Garrido, W. F. Heinz, A. E. Ryan, J. M. Weiss, et al., *Proc. Natl. Acad. Sci.* **2017**, *114*, 201709119.
- [20] D. Mazhar, R. Ang, J. Waxman, *Br. J. Cancer* **2006**, *94*, 346–350.
- [21] N. L. Patel, J. Stevens, D. C. Haines, J. Kalen, S. Seaman, E. Zudaire, M. B. Hilton, T. P. Conrads, D. Logsdon, B. St. Croix, et al., *Sci. Transl. Med.* **2014**, *6*, 242ra84.
- [22] L. R. Howe, S. H. Chang, K. C. Tolle, R. Dillon, L. J. T. Young, R. D. Cardiff, R. A. Newman, P. Yang, H. T. Thaler, W. J. Muller, et al., *Cancer Res.* **2005**, *65*, 10113–10119.
- [23] W. L. Smith, Y. Urade, P.-J. Jakobsson, *Chem. Rev.* **2011**, *111*, 5821–5865.
- [24] C. Yuan, C. J. Rieke, G. Rimon, B. A. Wingerd, W. L. Smith, *Proc. Natl. Acad. Sci.* **2006**, *103*, 6142–6147.
- [25] C. Yuan, R. S. Sidhu, D. V. Kuklev, Y. Kado, M. Wada, I. Song, W. L. Smith, *J. Biol. Chem.* **2009**, *284*, 10046–10055.
- [26] L. Dong, C. Yuan, B. J. Orlando, M. G. Malkowski, W. L. Smith, *J. Biol. Chem.* **2016**, *291*, 25641–25655.
- [27] L. Dong, H. Zou, C. Yuan, Y. H. Hong, D. V. Kuklev, W. L. Smith, *J. Biol. Chem.* **2016**, *291*, 4069–4078.
- [28] T. J. McCarthy, A. U. Sherif, M. J. Graneto, J. J. Talley, M. J. Welch, *J. Nucl. Med.* **2002**, *43*, 117–124.
- [29] E. F. J. de Vries, A. van Waarde, A. R. Buursma, W. Vaalburg, *J. Nucl. Med.* **2003**, *44*, 1700–6.
- [30] J. Prabhakaran, M. D. Underwood, R. V. Parsey, V. Arango, V. J. Majo, N. R. Simpson, R. Van Heertum, J. J. Mann, J. S. D. Kumar, *Bioorg. Med. Chem.* **2007**, *15*, 1802–1807.
- [31] H. M. Schuller, G. Kabalka, G. Smith, A. Mereddy, M. Akula, M. Cekanova, *ChemMedChem* **2006**, *1*, 603–610.
- [32] F. Wuest, T. Knies, R. Bergmann, J. Pietzsch, *Bioorg. Med. Chem.* **2008**, *16*, 7662–7670.
- [33] E. F. J. de Vries, J. Doorduyn, R. A. Dierckx, A. van Waarde, *Nucl. Med. Biol.* **2008**, *35*, 35–42.
- [34] J. S. Dileep Kumar, B. Bai, F. Zanderigo, C. DeLorenzo, J. Prabhakaran, R. Parsey, J. J. Mann, *Molecules* **2018**, *23*, 1929.
- [35] M. J. Uddin, B. C. Crews, A. L. Blobaum, P. J. Kingsley, D. L. Gordon, J. O. McIntyre, L. M. Matrisian, K. Subbaramaiah, A. J. Dannenberg, D. W. Piston, et al., *Cancer Res.* **2010**, *70*, 3618–3627.
- [36] M. J. Uddin, B. C. Crews, K. Ghebreselasie, L. J. Marnett, *Bioconjug. Chem.* **2013**, *24*, 712–723.
- [37] H. Zhang, J. Fan, J. Wang, B. Dou, F. Zhou, J. Cao, J. Qu, Z. Cao, W. Zhao, X. Peng, *J. Am. Chem. Soc.* **2013**, *135*, 17469–17475.
- [38] H. Zhang, J. Fan, J. Wang, S. Zhang, B. Dou, X. Peng, *J. Am. Chem. Soc.* **2013**, *135*, 11663–11669.
- [39] A. T. Aron, A. G. Reeves, C. J. Chang, *Curr. Opin. Chem. Biol.* **2018**, *43*, 113–118.
- [40] T. A. Su, K. J. Brummer, C. J. Chang, *Curr. Opin. Biotechnol.* **2019**, *60*, 198–204.
- [41] W. Chyan, R. T. Raines, *ACS Chem. Biol.* **2018**, *13*, 1810–1823.
- [42] Z. R. Dai, G. B. Ge, L. Feng, J. Ning, L. H. Hu, Q. Jin, D. D. Wang, X. Lv, T. Y. Dou, J. N. Cui, et al., *J. Am. Chem. Soc.* **2015**, *137*, 14488–14495.
- [43] J. Ning, T. Liu, P. Dong, W. Wang, G. Ge, B. Wang, Z. Yu, L. Shi, X. Tian, X. Huo, et al., *J. Am. Chem. Soc.* **2019**, *141*, 1126–1134.
- [44] L. Li, C. W. Zhang, G. Y. J. Chen, B. Zhu, C. Chai, Q. H. Xu, E. K. Tan, Q. Zhu, K. L. Lim, S. Q. Yao, *Nat. Commun.* **2014**, *5*, 3276.
- [45] L. Li, C. W. Zhang, J. Ge, L. Qian, B. H. Chai, Q. Zhu, J. S. Lee, K. L. Lim, S. Q. Yao, *Angew. Chemie - Int. Ed.* **2015**, *54*, 10821–10825.
- [46] C. Anorma, J. Hedhli, T. E. Bearrood, N. W. Pino, S. H. Gardner, H. Inaba, P. Zhang, Y. Li, D. Feng, S. E. Dibrell, et al., *ACS Cent. Sci.* **2018**, *4*, 1045–1055.
- [47] K. E. Furse, D. A. Pratt, N. A. Porter, T. P. Lybrand, *Biochemistry* **2006**, *45*, 3189–3205.
- [48] R. J. Kulmacz, W. A. van der Donk, A. L. Tsai, *Prog. Lipid Res.* **2003**, *42*, 377–404.
- [49] H. H. Gorris, D. R. Walt, *J. Am. Chem. Soc.* **2009**, *131*, 6277–6282.
- [50] D. Debski, R. Smulik, J. Zielonka, B. Michałowski, M. Jakubowska, K. Debowska, J. Adamus, A. Marcinek, B. Kalyanaraman, A. Sikora, *Free Radic. Biol. Med.* **2016**, *95*, 323–332.
- [51] D. Picot, P. J. Loll, R. M. Garavito, *Nature* **1994**, *367*, 243–249.
- [52] K. J. Rieke, A. M. Mulichak, R. M. Garavito, W. L. Smith, *J. Biol. Chem.* **1999**, *274*, 17109–17114.
- [53] D. K. Bhattacharyya, M. Lecomte, C. J. Rieke, R. M. Garavito, W. L. Smith, *J. Biol. Chem.* **1996**, *271*, 2179–2184.
- [54] M. Yu, D. Ives, C. S. Ramesha, *Biochemistry* **1997**, *272*, 21181–21186.
- [55] Y. Hitomi, T. Takeyasu, T. Funabiki, M. Kodera, *Anal. Chem.* **2011**, *83*, 9213–9216.
- [56] A. V. Klotz, J. J. Stegeman, C. Walsh, *Anal. Biochem.* **1984**, *140*, 138–145.
- [57] S. S. Ayoub, R. J. Flower, M. P. Seed, *Cyclooxygenases. Methods in Molecular Biology (Methods and Protocols)*, **2010**.
- [58] J. Jiang, G. G. Borisenko, A. Osipov, I. Martin, R. Chen, A. A. Shvedova, A. Sorokin, Y. Y. Tyurina, A. Potapovich, V. A. Tyurin, et al., *J. Neurochem.* **2004**, *90*, 1036–1049.
- [59] J. A. Mancini, D. Riendeau, J.-P. P. Falgoutyret, P. J. Vickers, G. P. O'Neill, J.-P. P. Falgoutyret, P. J. Vickers, G. P. O'Neill, *J. Biol. Chem.* **1995**, *270*, 29372–29377.
- [60] W. F. Hood, J. K. Gierse, P. C. Isakson, J. R. Kiefer, R. G. Kurumbail, K. Seibert, J. B. Monahan, *Mol. Pharmacol.* **2003**, *63*, 870–877.
- [61] D. R. McDougall, J. E. Watson, A. A. Abdeen, R. Adili, M. P. Caputo, J. E. Krapf, R. W. Johnson, K. A. Kilian, M. Holinstat, A. Das, *Proc. Natl. Acad. Sci.* **2017**, *114*, E6034–E6043.
- [62] T. V. Votyakova, I. J. Reynolds, *Arch. Biochem. Biophys.* **2004**, *431*, 138–144.
- [63] G. Cingolani, A. Panella, M. G. Perrone, P. Vitale, G. Di Mauro, C. G. Fortuna, R. S. Armen, S. Ferorelli, W. L. Smith, A. Scilimati, *Eur. J. Med. Chem.* **2017**, *138*, 661–668.
- [64] B. J. Orlando, M. G. Malkowski, *Acta Crystallogr. Sect. F Struct. Biol. Commun.* **2016**, *72*, 772–776.
- [65] H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, *Nucleic Acids Res.* **2000**, *28*, 235–242.
- [66] O. Trott, A. J. Olson, *J. Comput. Chem.* **2010**, *31*, 455–461.
- [67] S. Xu, M. J. J. Uddin, S. Banerjee, L. J. L. J. Marnett, M. Jashim Uddin, S. Banerjee, K. Duggan, J. Musee, J. R. Kiefer, K. Ghebreselasie, et al., *J. Biol. Chem.* **2019**, *294*, 8690–8689.
- [68] B. Chance, *Arch. Biochem. Biophys.* **1952**, *41*, 416–424.
- [69] J. N. Rodriguez-Lopez, M. A. Gilabert, J. Tudela, R. N. F. Thorneley, F. Garcia-Canovas, *Biochemistry* **2000**, *39*, 13201–13209.
- [70] A. J. Vecchio, D. M. Simmons, M. G. Malkowski, *J. Biol. Chem.* **2010**, *285*, 22152–22163.
- [71] L. Yuan, W. Lin, S. Zhao, W. Gao, B. Chen, L. He, S. Zhu, *J. Am. Chem. Soc.* **2012**, *134*, 13510–23.
- [72] D. Tsikas, M. T. Suchy, J. Niemann, P. Tossios, Y. Schneider, S. Rothmann, F. M. Gutzki, J. C. Frölich, D. O. Stichtenoth, *FEBS Lett.* **2012**, *586*, 3723–3730.
- [73] E. P. Ryan, T. P. Bushnell, A. E. Friedman, I. Rahman, R. P. Phipps, *Cancer Immunol. Immunother.* **2008**, *57*, 347–358.
- [74] G. O. Dengiz, F. Odabasoglu, Z. Halici, H. Suleyman, E. Cadirci, Y. Bayir, *Arch. Pharm. Res.* **2007**, *30*, 1426–1434.
- [75] O. Pastoris, M. Verri, F. Boschi, O. Kastsiuchenka, B. Balestra, F. Pace, M. Tonini, G. Natale, *Naunyn. Schmiedeberg's Arch. Pharmacol.* **2008**, *378*, 421–429.
- [76] I. T. Abdel-Raheem, *Basic Clin. Pharmacol. Toxicol.* **2010**, *107*, 742–750.
- [77] F. O. Martinez, S. Gordon, *F1000Prime Rep.* **2014**, *6*, 13.
- [78] M. J. Bienkowski, M. A. Petro, J. Robinson, *Biochemistry* **1989**, *264*, 6536–6544.
- [79] M. Giroux, A. Descoteaux, *J. Immunol.* **2000**, *165*, 3985–3991.
- [80] A. G. Eliopoulos, C. D. Dumitru, C. C. Wang, J. Cho, P. N. Tsichlis, *EMBO J.* **2002**, *21*, 4831–4840.
- [81] A. Grkovich, C. A. Johnson, M. W. Buczynski, E. A. Dennis, *J. Biol. Chem.* **2006**, *281*, 32978–32987.
- [82] C. A. Rouzer, A. T. Jacobs, C. S. Nirodi, P. J. Kingsley, J. D. Morrow, L. J. Marnett, *J. Lipid Res.* **2005**, *46*, 1027–1037.

RESEARCH ARTICLE


- [83] M. Font-Nieves, M. G. Sans-Fons, R. Gorina, E. Bonfill-Teixidor, A. Salas-Pédomo, L. Márquez-Kisinousky, T. Santalucia, A. M. Planas, *J. Biol. Chem.* **2012**, *287*, 6454–6468.
- [84] C. J. Smith, L. J. Marnett, *Arch. Biochem. Biophys.* **1996**, *335*, 342–350.
- [85] Y. Buchmuller-Rouiller, S. B. Corradin, J. Smith, P. Schneider, A. Ransijn, C. V. Jongeneel, J. Mauël, *Cell. Immunol.* **1995**, *164*, 73–80.
- [86] U. Butzer, H. Weidenbach, S. Gansauge, F. Gansauge, H. G. Beger, A. K. Nussler, *FEBS Lett.* **1999**, *445*, 274–278.
- [87] N. A. Trushkin, I. S. Filimonov, P. V. Vrzheschch, *Biochem.* **2010**, *75*, 1368–1373.
- [88] T. D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, J. R. Vane, *Proc. Natl. Acad. Sci.* **1999**, *96*, 7563–7568.
- [89] J. A. Mitchell, P. Akarasereenont, C. Thiemermann, R. J. Flower, J. R. Vane, *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 11693–11697.

RESEARCH ARTICLE

RESEARCH ARTICLE

Activity-based sensing of

Cyclooxygenase-2: An isoform-selective fluorogenic probe reports on enzymatic activity within live cells. Two-step activation facilitates the release of the natural product and resorufin for confocal imaging and flow cytometry. CoxFluor indicates that COX-2 activity can be regulated by oxygen without a change in protein expression level.



Anuj K. Yadav,⁺ Christopher J. Reinhardt,⁺ Andres S. Arango, Hannah C. Huff, Liang Dong, Michael G. Malkowski, Aditi Das, Emad Tajhorshid, Jefferson Chan*

Page No. – Page No.

An Activity-based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells